#Dapagliflozin in Patients with Heart Failure and Reduced #Ejection Fraction
In patients with type 2 diabetes, inhibitors of sodiumβglucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms.. A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 … Continue reading #Dapagliflozin in Patients with Heart Failure and Reduced #Ejection Fraction